Business
Directorate Changes
Directorate Changes.
About this update from Valirx Plc
[{"type":"text","content":"\n\nValiRx plc\n \n(\"ValiRx\" or the \"Company\")\n \nDirectorate Changes\n \nValiRx plc (the \"Company\") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to announce that Martin Gouldstone, a current Independent Non-Executive Director of the Company, has been appointed Independent Non-Executive Chairman with immediate effect.\n \nIn addition, the Company announces that Cathy Tralau-Stewart has been appointed to the Board as Executive Director with immediate effect and Dr Mark Eccleston is proposed to the join the Board as Chief Executive Officer subject to standard regulatory due diligence.\n \nDr Mark Eccleston\n \nMark has worked as a scientific consultant and served on both the Commercial and Scientific Advisory Boards of ValiRx and Inaphaea gaining comprehensive knowledge of the Company's development programmes.\n \nWith over 30 years' experience working in translation science in both drug and biomarker development, Mark is a former BBSRC Enterprise fellow and holds an MBA (Entrepreneurship). He is an inventor of 26 published patents ranging from peptide and CAR-T cell therapies to nucleosome enrichment as well as biodegradable chewing gum.\n \nMark is the Managing Director of OncoLytika Ltd, a UK based technology consultancy company with a successful track record of securing grant funding (close to €3 million in Eurostar funding), strategic business development and client project management. He is also a scientific founder of several companies, including Volition, US listed biomarker company established as a spin out from ValiRx which reached a peak valuation of over $250 million. Mark currently serves as an independent scientific advisor supporting Nu.Q®️ Discover services and sits on Volition's Scientific Advisory Board as well as being a shareholder.\n \nIn addition to his commercial activities, Mark has supervised multiple industry funded PhD and Masters students at various universities, including the Open University, Greenwich University and DKFZ in Germany. He also serves as an external advisor to the Open University, contributing to modules focused on employability of biosciences graduates and employer expectations from graduates in terms of bioinformatics training.\n \nFurther to the announcement on 19 ...